Orgenesis Inc. (ORGS): Price and Financial Metrics


Orgenesis Inc. (ORGS): $2.02

-0.10 (-4.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ORGS Stock Summary

  • ORGS has a higher market value than merely 12.85% of US stocks; more precisely, its current market capitalization is $51,602,425.
  • With a year-over-year growth in debt of -51.72%, ORGENESIS INC's debt growth rate surpasses just 5.2% of about US stocks.
  • Over the past twelve months, ORGS has reported earnings growth of -108.67%, putting it ahead of just 13.62% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ORGENESIS INC are SNCE, RVP, INDO, IVDA, and XOMA.
  • Visit ORGS's SEC page to see the company's official filings. To visit the company's web site, go to www.orgenesis.com.

ORGS Valuation Summary

  • ORGS's EV/EBIT ratio is -10.7; this is 205.42% lower than that of the median Healthcare stock.
  • Over the past 132 months, ORGS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ORGS.

Stock Date P/S P/B P/E EV/EBIT
ORGS 2023-01-30 2.0 2.0 -10.4 -10.7
ORGS 2023-01-27 2.1 2.0 -10.6 -11.0
ORGS 2023-01-26 2.1 2.0 -10.7 -11.0
ORGS 2023-01-25 2.2 2.1 -11.1 -11.5
ORGS 2023-01-24 2.2 2.1 -11.1 -11.4
ORGS 2023-01-23 2.3 2.2 -11.4 -11.8

ORGS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ORGS has a Quality Grade of F, ranking ahead of 4.67% of graded US stocks.
  • ORGS's asset turnover comes in at 0.277 -- ranking 161st of 677 Pharmaceutical Products stocks.
  • ACRX, ASMB, and JNJ are the stocks whose asset turnover ratios are most correlated with ORGS.

The table below shows ORGS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.277 0.850 4.262
2021-03-31 0.156 1.388 7.853
2020-12-31 0.070 1.000 -0.286
2020-09-30 0.128 0.792 -3.802
2020-06-30 0.209 0.571 -3.077
2020-03-31 0.290 0.495 -3.168

ORGS Price Target

For more insight on analysts targets of ORGS, see our ORGS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.00 Average Broker Recommendation 1.5 (Moderate Buy)

ORGS Stock Price Chart Interactive Chart >

Price chart for ORGS

ORGS Price/Volume Stats

Current price $2.02 52-week high $4.04
Prev. close $2.12 52-week low $1.13
Day low $2.02 Volume 15,200
Day high $2.16 Avg. volume 35,617
50-day MA $2.15 Dividend yield N/A
200-day MA $2.06 Market Cap 51.60M

Orgenesis Inc. (ORGS) Company Bio


Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company was founded in 2008 and is based in Germantown, Maryland.


ORGS Latest News Stream


Event/Time News Detail
Loading, please wait...

ORGS Latest Social Stream


Loading social stream, please wait...

View Full ORGS Social Stream

Latest ORGS News From Around the Web

Below are the latest news stories about ORGENESIS INC that investors may wish to consider to help them evaluate ORGS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!

William White on InvestorPlace | January 18, 2023

Investors in Orgenesis (NASDAQ:ORGS) have unfortunately lost 73% over the last five years

It is doubtless a positive to see that the Orgenesis Inc. ( NASDAQ:ORGS ) share price has gained some 44% in the last...

Yahoo | January 4, 2023

Orgenesis and Kurve Therapeutics Announce Pre-Clinical Study Results for a Cell-Based Oncolytic Virus Bearing Product Demonstrating Over 50% Reduction in a Murine Glioblastoma Model

Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technologyGERMANTOWN, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing pr

Yahoo | December 20, 2022

Orgenesis Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Orgenesis ( NASDAQ:ORGS ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.99m (down 7.9% from 3Q 2021...

Yahoo | November 16, 2022

Loss-Making Orgenesis Inc. (NASDAQ:ORGS) Expected To Breakeven In The Medium-Term

Orgenesis Inc. ( NASDAQ:ORGS ) is possibly approaching a major achievement in its business, so we would like to shine...

Yahoo | November 12, 2022

Read More 'ORGS' Stories Here

ORGS Price Returns

1-mo -8.18%
3-mo 43.26%
6-mo 21.69%
1-year -39.52%
3-year -59.19%
5-year -76.24%
YTD 3.59%
2022 -32.29%
2021 -36.00%
2020 -3.43%
2019 -0.43%
2018 -18.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.874 seconds.